Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jun;79(6):1560-1572.
doi: 10.1111/all.16108. Epub 2024 Apr 2.

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

Emma Guttman-Yassky  1 , Kenji Kabashima  2 , Delphine Staumont-Salle  3 , Walter K Nahm  4 , Sylvia Pauser  5 , Joel Correa Da Rosa  6 , Britta Cathrina Martel  7 , Daniel Elenius Madsen  7 , Mads Røpke  7 , Petra Arlert  7 , Louise Steffensen  7 , Andrew Blauvelt  8 , Kristian Reich  9
Affiliations
Clinical Trial

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years

Emma Guttman-Yassky et al. Allergy. 2024 Jun.

Abstract

Background: Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2-year impacts of IL-13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate-to-severe AD.

Methods: Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long-term extension ECZTEND (NCT03587805) trials. Gene expression was assessed by RNA sequencing; protein expression was assessed by immunohistochemistry and immunoassay.

Results: Tralokinumab improved the transcriptomic profile of lesional skin by Week 4. Mean improvements in the expression of genes dysregulated in AD were 39% at Week 16 and 85% at 2 years with tralokinumab, with 15% worsening at Week 16 with placebo. At Week 16, tralokinumab significantly decreased type 2 serum biomarkers (CCL17/TARC, periostin, and IgE), reduced epidermal thickness versus placebo, and increased loricrin coverage versus baseline. Two years of tralokinumab treatment significantly reduced expression of genes in the Th2 (IL4R, IL31, CCL17, and CCL26), Th1 (IFNG), and Th17/Th22 (IL22, S100A7, S100A8, and S100A9) pathways as well as increased expression of epidermal differentiation and barrier genes (CLDN1 and LOR). Tralokinumab also shifted atherosclerosis signaling pathway genes (SELE, IL-37, and S100A8) toward non-lesional expression.

Conclusion: Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13 in the pathogenesis of AD.

Clinical trial registration: NCT03131648, NCT03587805.

Keywords: atopic dermatitis; biomarkers; gene expression; tralokinumab; type 2 inflammation.

PubMed Disclaimer

References

REFERENCES

    1. Silverberg JI. Atopic dermatitis in adults. Med Clin North Am. 2020;104(1):157‐176. doi:10.1016/j.mcna.2019.08.009
    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345‐360. doi:10.1016/s0140-6736(20)31286-1
    1. Hjuler KF, Böttcher M, Vestergaard C, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. Am J Med. 2015;128(12):1325‐1334.e2. doi:10.1016/j.amjmed.2015.05.041
    1. Silverberg JI, Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol. 2015;135(3):721‐728.e6. doi:10.1016/j.jaci.2014.11.023
    1. Ewald DA, Malajian D, Krueger JG, et al. Meta‐analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. BMC Med Genet. 2015;8:60. doi:10.1186/s12920-015-0133-x

Publication types

Associated data

Grants and funding

LinkOut - more resources